Summary A total of 49 patients with paucibacillary leprosy (PB) who completed multidrug therapy (MDT) between 1985 and 1990 were analysed retrospectively for efficacy and complications; 20 (40·8%) patients had borderline-tuberculoid (BT), 13 (26· 5%) had tuberculoid (TT), I (2· 1 %) had indeterminate (I) and 15 (30·0%) had pure neural (N) leprosy; 26 patients (76·5% of 34 non-neural leprosy) were skin biopsied for histological cure before MDT was stopped. Of these 26 patients, 19 had histological clearance at 6 months while the remaining 7 cleared beyond I year (18-36 months). The remaining 8 non-neural patients who refused rebiopsy had MDT for 6-8 months and the MDT was stopped when there was clinical clearance. Of the 15 neural (N) leprosy patients, II were given MDT for 6 months while the rest had 12-18 months of treatment; I patient with neural leprosy, who was treated for 6 months, relapsed with BT leprosy 18 months post treatment.
Materials and methods
A total of 49 PB patients (according to the Ridley-Jopling classification) who completed MDT between June 1985 and May 1990 were analysed retrospectively for efficacy and complications. MDT consisted of rifampicin (600 mg monthly, taken under supervision), and dapsone (100 mg daily). Our treatment regime differed fr om the standard WHO recommendations in that MDT was not arbitarily terminated at 6 months but continued with regular assessment until histological or clinical cure, or both, were achieved.
Only newly-diagnosed PB patients who completed MDT were included in the study. All non-neural PB leprosy patients had both clinical and histological diagnosis ofleprosy, and 4 of our neural (N) leprosy patients had histological diagnosis while in the remaining II the diagnosis was made on clinical grounds. All patients were clinically assessed initially at 3 weeks for Lepromin Test reading and subsequently at monthly intervals. Baseline investigations included slit skin smears for acid-fast bacilli (AFB), lepromin test, Glucose 6-phosphatase deficiency (G6PD) screen, blood counts and liver function tests. At monthly fo llow-up visits the urine was checked for the presence of dapsone, and blood for haemoglobin and reticulocyte count. Liver function tests were done where indicated.
We considered fa iled MD T if the patients continued to develop new lesions, had a worsening of existing lesions, or developed new neurological deficits while on treatment. There should also have been an increase in histological activity. If the patients had some improvements while on MDT, they were not considered to be treatment fa ilures. These patients were not considered to have late reversal reactions as they had no initial improvement while on treatment. Patients who fa iled MD Twere treated with rifampicin 600 mg and clofazimine 300 mg under supervision monthly; and c10fazimine 100 mg 3 times a week with ethoionamide 375 mg per day, unsupervised.
Clinical cure for neural patients with grade 2 or 3 deformities (WHO definition) was defined arbitrarily when patients had recovery of sensory but not motor deficits.
As far as possible, post-treatment biopsy of the same site as at diagnosis was done after 6 months' treatment. If histological activity persists at 6 months rebiopsies should be repeated every 6 months or before MDT was stopped. After MDT was stopped all patients were fo llowed up at 6-12 monthly intervals for clinical relapse. Clinical relapse was defined as the emergence of new skin lesions with or without the increase in redness, thickness and diameter of existing skin lesions or new muscle paralysis. A histological diagnosis is needed to confirm clinical relapse. Patients are released from surveillance after being disease-free for 5 years.
Results
We had 20 (40·8%) patients with borderline-tuberculoid (BT), 13 (26·5%) with tuberculoid (TT), I (2· 1 %) with indeterminate (I) and 15 (30·6%) with neural (N) leprosy. There were 31 male patients and 18 female patients giving a male to female ratio of 1·7: 1. The age of onset ranged from 19 to 87 years. There were 37 Chinese (75·5%), 8 Malays (16·3%) and 4 Indians (8·2%) in the study, which reflected the racial composition in Singapore .
In all, 38 (77·6%) patients had 6 months of MDT while the remaining 11 (24·5%) had * Signifies that: 1 patient (biopsied proven, positive AFB) developed BT within 2 years; t I patient in each group had clinical and histological activity at 12 months therapy change to rifampicin and clofazimine (failed MDT treatment); 1: I patient had dapsone induced hepatitis within 6 months-clofazimine replaced dapsone; I patient had rifampicin and clofazimine (failed MDT treatment).
MDT from 12 to 30 months (T(!.ble I). Of the 38 patients who had 6 months of treatment, 19 had a clinicaI"and histological cure while the remaining 19 had clinical inactivity. Among the patients who received MDT for longer than 6 months, 4 were neural (N), 6 were BT and I was TT leprosy. Of these patients 3 were considered to have fa iled MD T treatment after 6 or 12 months and given rifampicin and clofazimine instead, 2 patients had BT and I patient had leprosy (Table I) .
The BT leprosy patients tend to achieve histological clearance at a later date-of the 20 patients 6 cleared after 18-30 months' treatment. Only I of the 13 TT leprosy patient required treatment after 6 months. This patient had activity at 12 months which cleared after he was given rifampicin and clofazimine for 6 months; II of the 15 neural patients had MDT for 6 months while the remaining 4 had 12-18 months of MDT. However, I neural patient with Grade I deformity (sural nerve biopsied proven and acid fa st bacilli positive) who had 6 months of MDT, relapsed with BT leprosy 18 months later. He had had no previous skin lesions but now presented with new skin lesions. He was re-treated with rifampicin and clofazimine.
The complications of treatment are summarized in Table 2 . Only 4 (8,2%) patients had drug reactions-I (2,0%) had dapsone syndrome, I (2,0%) had dapsone hepatitis and 2 (4·1 %) had haemolytic anaemia (both are G6PD positive); 7 (14,3%) patients, all of whom had BT leprosy, developed Type I reactions. The efficacy of MDT has been generally accepted. Some authors4,6 accepted it with some reservation mainly with regard to the duration of therapy. In Singapore, leprosy is being treated only in a single government centre and here clinical and histological assessment could be done before stopping therapy. We do not stop treatment abruptly at 6 months if there is evidence of clinical or histological activity. After 6 months of MDT we had a cure rate of 77·6% (38 patients) while 22·4% (1 1 patients) had either clinical or histological activity. Other authors2-4,7 also have had similar experiences with the persistence of disease at the end of 6 months of MDT, ranging from 6·5% to more than 30%. However, our cure rates improved when MDT was continued after 6 months, with cure rates of 83·7% at 12 months, 89·8% at 18 months, 95·9% at 24 months and 100% at 30 months (Table 1) . Other field studies2•3,7 continued with dapsone monotherapy or MDT after 6 months until clinical cure. They too, showed a further increase in cure rates ranging from 6·5% to 57% (Table 3 ), suggesting that 6 months of MDT might not be adequate.
Discussion
Of the patients who required more than 6 months of treatment, 6 had BT, 1 had TT, 1 had indeterminate and 4 had neural leprosy. The 6 BT patients had treatment beyond 18 months, 2 of whom required fa iled MD T treatment and 1 had clofazimine instead of dapsone (as he had dapsone induced hepatitis). Repeated biopsies at 6-monthly intervals from these BT patients showed histological activity beyond 12 months. This suggested that some BT patients required a longer duration of treatment. Revankar8 fo und disease activity among 17% of his BT patients 3 years after MDT. He also suggested that BT leprosy should be treated longer. Studies3,9,IO have also shown that BT leprosy patients have a higher rate of relapse compared to other groups. However, no relapse was observed among our BT patients, probably because of our extended treatment period.
In total, 11 of our 15 neural patients had only 6 months of MDT. These patients had recovery of sensory deficits. However, I of these patients developed BT within 2 years (sural nerve biopsy showed AFB). He was re-treated with rifampicin and c1ofazimine. Whether neural patients, especially those with positive AFB, should be treated beyond 6 months is still uncertain.
It could be argued that patients who still had clinical or histological activity at 6 months might continue to improve even if MDT was then stopped. As this is a retrospective study with no such control groups, there is no way of knowing this. However, it seemed unlikely as 10 of these patients had neural or BT leprosy. It had been suggested that both these groups of patients require longer periods of treatment to prevent relapse.8 Besides, we and others,2-4,7 had shown that disease activity persisted beyond 6 months of MDT.
Our relapse rate is low (2%) compared to others ( Table 4) . This might be due to the fact that treatment was individualized and extended where necessary. We fo llowed up 34 patients (69,4%) for at least 2 years post-treatment.
MDT appeared safe as only 4 (8,2%) of our patients developed reactions to dapsone. No reaction to rifampicin or c10fazimine was reported. The 2 patients who developed dapsone-induced haemolytic anaemia were G6PD positive and haemolysis was dose related. No haemolysis recurred when dapsone was reduced to 50 mg daily. Hypersensiti vity reaction to dapsone occurs in less than 0·5% of those taking the drugs, and usually begins 1-4 weeks after administration of the drug.
We concluded from our data that short-term WHO MDT is effective and safe. We have a cure rate of77·6% at 6 months of MDT, a low relapse rate of2% and a complication rate of 8·2% (from dapsone). We agree with others3,14 that the duration of MDT should be tailored to the individual. It should not be arbitrarily stopped at 6 months, and extended periods of treatment may be necessary, especially in some cases of BT leprosy.
